IL6ST and pancreatic neoplasm: The median overall survival for PDAC patients with no stromal gp130 expression was 16.2 (IQR 8.7–34.2) months, whereas for patients expressing stromal gp130 in the pancreatic tumors was 22.9 (IQR 12.2–117.6) months (p = 0.144).